Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

Apple convinced a federal jury on Friday that health monitoring tech company Masimo's smartwatches infringe two of its design patents. The jury, in Delaware, agreed with Apple that Masimo's W1 and ...

The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of ...

Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally poached its employees and stole trade secrets when developing the ...

The lawsuit resulted in five of Masimo’s claims being rejected, and a jury being unable to reach agreement on the rest. That will see a new trial held, at a date yet to be set. Masimo got its ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

REUTERS/Manuel Orbegozo/File Photo By Blake Brittain Apple convinced a federal jury on Friday that health monitoring tech company Masimo's smartwatches infringe two of its design patents.

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will ...

A federal jury ruled Friday that Masimo smartwatches infringed Apple patents, but Apple isn’t getting a big payday. Bloomberg Law reports that the company was only seeking the statutory minimum ...